Answers are grounded in this paper and cite their sources.
Atherosclerosis (AS) remains a leading cause of cardiovascular mortality. Residual inflammatory risk persists despite optimal lipid‐lowering therapy, largely because macrophage phenotypes extend beyond the simple M1/M2 classification. TCM can reset macrophage polarization through multiple targets, but existing reviews treat epigenetic, metabolic, and signaling events as separate modules and do not integrate how herbal agents coordinate these layers. We screened literature published from 2010 to 2026 in multiple languages. We summarize three interconnected mechanisms of TCM action: (i) epigenetic remodeling through DNA methylation, non‐coding RNAs, and histone modifications; (ii) metabolic reprogramming that shifts macrophages from glycolysis toward fatty acid oxidation and oxidative phosphorylation; and (iii) suppression of pro‐inflammatory cascades (NF‐κB, JAK/STAT, MAPK, Notch, PI3K/Akt/mTOR, and cGAS‐STING) together with activation of PPARγ‐mediated reparative signaling. We highlight metabolite‐driven histone modifications, particularly acetyl‐CoA/NAD + ‐dependent chromatin remodeling and H3K18 lactylation, as key under‐appreciated mechanistic links through which herbal formulas exert network‐level immunomodulation rather than single‐pathway inhibition. Preclinical plaque‐stabilizing effects have been reported, but inter‐species differences, poorly characterized active metabolites, and the scarcity of non‐invasive in vivo validation remain major barriers to translation. We propose a roadmap that combines humanized myeloid models, AI‐assisted multi‐omics, and smart nano‐delivery systems. This review provides a three‐dimensional mechanistic framework for multi‐target TCM action in AS and supports the development of precision cardio‐immunology.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: